Patient characteristics
| . | Total cohort . | IDH1R132 wild-type . | IDH1R132 mutated . | Significant difference . |
|---|---|---|---|---|
| All patients | 1414 | 1321/93.4% | 93/6.6% | |
| Female | 668 (47.2%) | 610/91.3% | 58/8.7% | ↑ P = .003 |
| Male | 746 (52.8%) | 711/95.3% | 35/4.7% | ↓ P = .003 |
| Median age, y (range) | 65.8 (17.1-93.3) | 65.7 (17.1-93.3) | 67.2 (21.8-85.8) | n.s. |
| Median WBC, × 109/L (range) | 8400 (300-600 000) | 8600 (400-600 000) | 5000 (300-255 000) | n.s. |
| Median platelets, × 109/L (range) | 55 000 (1000-1 160 000) | 55 000 (1000-1 160 000) | 74,000 (13 000- 571 000) | n.s. |
| FAB subtype, n/% | ||||
| Total available | 1180 | 1100 | 80 | |
| AML M0 | 66/5.6% | 63/95.5% | 3/4.5% | n.s. |
| AML M1 | 274/23.2% | 232/84.7% | 42/15.3% | ↑ P < .001 |
| AML M2 | 432/36.6% | 405/93.8% | 27/6.2% | n.s. |
| AML M3 | 88/7.5% | 86/97.7% | 2/2.3% | ↓ P = .050 |
| AML M4 | 171/14.5% | 167/97.7% | 4/2.3 % | ↓ P = .013 |
| AML M4eo | 51/4.3% | 51/100% | 0 | ↓ P = .045 |
| AML M5a | 22/1.9% | 22/100% | 0 | n.s. |
| AML M5b | 22/1.9% | 22/100% | 0 | n.s. |
| AML M6 | 51/4.3% | 50/98.0% | 1/2.0% | n.s. |
| AML M7 | 3/0.3% | 2 | 1 | n.s. |
| History | ||||
| De novo | 1170/82.7% | 1090/93.2% | 80/6.8% | n.s. |
| s-AML after MDS | 120/8.5% | 111/92.5% | 9/7.5% | n.s. |
| s-AML after MPN | 37/2.6% | 35/94.6% | 2/5.4% | n.s. |
| t-AML after previous malignancy | 87/6.2% | 85/97.7% | 2/2.3% | n.s. |
| Cytogenetics | 1414 | |||
| Normal karyotype | 673/47.6% | 606/90.0% | 67/10.0% | ↑ P < .001 |
| t(15;17)/PML-RARA | 88/6.2% | 86/97.7% | 2/2.3% | ↓ P = .005 |
| t(8;21)/RUNX1-RUNX1T1 | 84/5.9% | 84/100% | 0 | ↓ P = .005 |
| inv(16)/t(16;16)/CBFB-MYH11 | 57/4.0% | 57/100% | 0 | ↓ P = .029 |
| t(11q23)/MLL | 31/2.2% | 31/100% | 0 | n.s. |
| t(6;9)/DEK-CAN | 5/0.4% | 5/100% | 0 | n.s. |
| t(8;16)/MYST3-CBP | 3/0.2% | 3/100% | 0 | n.s. |
| inv(3)/t(3;3) | 15/1.1% | 15/100% | 0 | n.s. |
| Trisomy 8 | 30/2.1% | 25/83.3% | 5/16.7% | ↑ P = .042 |
| Trisomy 13 | 12/0.8% | 11/91.7% | 1/8.3 % | n.s. |
| Other trisomies | 23/1.6% | 18/78.3 | 5/21.7% | n.s. |
| -7/7q- | 32/2.3% | 28/87.5% | 4/12.5% | n.s. |
| del(5q) | 6/0.4% | 6/100% | 0 | n.s. |
| del(9q) | 4/0.3% | 4/100% | 0 | n.s. |
| del(20q) | 2/0.1% | 2 | 0 | n.s. |
| All others including trisomies, monosomies, deletions or combinations of these | 61/4.3% | 55/90.2% | 6/9.8% | ↑ P = .010 |
| Complex aberrant | 288/20.4% | 285/99% | 3/1.0% | ↓ P < .001 |
| . | Total cohort . | IDH1R132 wild-type . | IDH1R132 mutated . | Significant difference . |
|---|---|---|---|---|
| All patients | 1414 | 1321/93.4% | 93/6.6% | |
| Female | 668 (47.2%) | 610/91.3% | 58/8.7% | ↑ P = .003 |
| Male | 746 (52.8%) | 711/95.3% | 35/4.7% | ↓ P = .003 |
| Median age, y (range) | 65.8 (17.1-93.3) | 65.7 (17.1-93.3) | 67.2 (21.8-85.8) | n.s. |
| Median WBC, × 109/L (range) | 8400 (300-600 000) | 8600 (400-600 000) | 5000 (300-255 000) | n.s. |
| Median platelets, × 109/L (range) | 55 000 (1000-1 160 000) | 55 000 (1000-1 160 000) | 74,000 (13 000- 571 000) | n.s. |
| FAB subtype, n/% | ||||
| Total available | 1180 | 1100 | 80 | |
| AML M0 | 66/5.6% | 63/95.5% | 3/4.5% | n.s. |
| AML M1 | 274/23.2% | 232/84.7% | 42/15.3% | ↑ P < .001 |
| AML M2 | 432/36.6% | 405/93.8% | 27/6.2% | n.s. |
| AML M3 | 88/7.5% | 86/97.7% | 2/2.3% | ↓ P = .050 |
| AML M4 | 171/14.5% | 167/97.7% | 4/2.3 % | ↓ P = .013 |
| AML M4eo | 51/4.3% | 51/100% | 0 | ↓ P = .045 |
| AML M5a | 22/1.9% | 22/100% | 0 | n.s. |
| AML M5b | 22/1.9% | 22/100% | 0 | n.s. |
| AML M6 | 51/4.3% | 50/98.0% | 1/2.0% | n.s. |
| AML M7 | 3/0.3% | 2 | 1 | n.s. |
| History | ||||
| De novo | 1170/82.7% | 1090/93.2% | 80/6.8% | n.s. |
| s-AML after MDS | 120/8.5% | 111/92.5% | 9/7.5% | n.s. |
| s-AML after MPN | 37/2.6% | 35/94.6% | 2/5.4% | n.s. |
| t-AML after previous malignancy | 87/6.2% | 85/97.7% | 2/2.3% | n.s. |
| Cytogenetics | 1414 | |||
| Normal karyotype | 673/47.6% | 606/90.0% | 67/10.0% | ↑ P < .001 |
| t(15;17)/PML-RARA | 88/6.2% | 86/97.7% | 2/2.3% | ↓ P = .005 |
| t(8;21)/RUNX1-RUNX1T1 | 84/5.9% | 84/100% | 0 | ↓ P = .005 |
| inv(16)/t(16;16)/CBFB-MYH11 | 57/4.0% | 57/100% | 0 | ↓ P = .029 |
| t(11q23)/MLL | 31/2.2% | 31/100% | 0 | n.s. |
| t(6;9)/DEK-CAN | 5/0.4% | 5/100% | 0 | n.s. |
| t(8;16)/MYST3-CBP | 3/0.2% | 3/100% | 0 | n.s. |
| inv(3)/t(3;3) | 15/1.1% | 15/100% | 0 | n.s. |
| Trisomy 8 | 30/2.1% | 25/83.3% | 5/16.7% | ↑ P = .042 |
| Trisomy 13 | 12/0.8% | 11/91.7% | 1/8.3 % | n.s. |
| Other trisomies | 23/1.6% | 18/78.3 | 5/21.7% | n.s. |
| -7/7q- | 32/2.3% | 28/87.5% | 4/12.5% | n.s. |
| del(5q) | 6/0.4% | 6/100% | 0 | n.s. |
| del(9q) | 4/0.3% | 4/100% | 0 | n.s. |
| del(20q) | 2/0.1% | 2 | 0 | n.s. |
| All others including trisomies, monosomies, deletions or combinations of these | 61/4.3% | 55/90.2% | 6/9.8% | ↑ P = .010 |
| Complex aberrant | 288/20.4% | 285/99% | 3/1.0% | ↓ P < .001 |
MDS indicates myelodysplastic syndrome; and MPN, myeloproliferative neoplasm; ↑ indicates elevated; and ↓, decreased.